Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum

By sjmartinez • January 6, 2024

Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa Junior MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S; IMPAACT 2010/VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093/cid/ciae001. Epub ahead of print. PMID: 38180851.

Tags: adverse pregnancy outcomes, antepartum weight change, HIV, Infectious Diseases, postpartum weight, Publications, Women’s health

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]